Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165190 · ClinicalTrials.gov registry record
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
A clinical trial, sponsored by Arizona State University.
- Completed
- Registry status
- 20
- Enrollment target
NCT01165190 is a clinical trial that has completed, run by Arizona State University. The registered enrollment target is 20 participants.
The verdict
NCT01165190 has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue. Moreover, in adipose tissue mitochondrial dysfunction results in decreased fatty acid oxidation and triglyceride synthesis, leading to increased circulating fatty acid concentrations, which in turn also leads to lipid accumulation inside muscle tissue. Lipid accumulation inside muscle tissue interferes with the insulin signaling pathway and causes insulin resistance. Mitochondrial dysfunction in both tissues has therefore been proposed to play an important role in insulin resistance in humans. Pioglitazone, a thiazolidinedione, is an FDA approved medication for the treatment of type 2 diabetes. It improves muscle insulin sensitivity at least in part by lowering intramuscular lipid concentrations but the mechanism by which this occurs is unclear. In the present study, we shall therefore test the hypothesis that pioglitazone improves mitochondrial function in muscle and adipose tissue in humans who are insulin resistant.
Interventions
- OTHER pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165190
The ClinicalTrials.gov registry entry for NCT01165190 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pioglitazone is the first listed.
NCT01165190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165190 about?
NCT01165190 is a clinical study titled "Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans". Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue. Moreover, in adipose tissue mitochondrial dysfunction results in decreased fatty acid oxidation and tr...
What is the current status of trial NCT01165190?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2008-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01165190?
The interventions under investigation include: pioglitazone (OTHER).
Who is sponsoring clinical trial NCT01165190?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.